Identifikatoren & physikalische Daten
| CAS No. | 70024-40-7 |
|---|
| Summenformel | C19H30ClN5O6 |
|---|
| Durchschnittliche Molmasse | 459,9 g/mol |
|---|
| Monoisotopische Masse | 459,18846136 g/mol |
|---|
| SMILES | COc1cc2nc(N3CCN(C(=O)C4CCCO4)CC3)nc(N)c2cc1OC.Cl.O.O |
|---|
| InChIKey | NZMOFYDMGFQZLS-UHFFFAOYSA-N |
|---|
| PubChem CID | 63016 |
|---|
| ChEMBL | CHEMBL1201091 |
|---|
| DTXSID | DTXSID801366621 |
|---|
Chemische & physikalische Eigenschaften
| Polarare Oberfläche (TPSA) | 105 |
|---|
| H-Brücken-Donoren | 4 |
|---|
| H-Brücken-Akzeptoren | 10 |
|---|
| Frei drehbare Bindungen | 4 |
|---|
| Schwere Atome | 31 |
|---|
| Formalladung | 0 |
|---|
| Komplexität | 544 |
|---|
| Human Drugs | FDA approved drugs -> Active ingredient |
|---|
Sicherheit & Vorschriften
| Treatment | Should overdosage of Terazosin lead to hypotension, support of the cardiovascular system is of first importance. Restoration of blood pressure and normalization of heart rate may be accomplished by keeping the patient in the supine position. If this measure is inadequate, shock should first be treated with volume expanders. If necessary, vasopressors should then be used and renal function should be monitored and supported as needed. Laboratory data indicate that Terazosin is highly protein boundtherefore, dialysis may not be of benefit. (L1712) |
|---|
| Gesundheitliche Auswirkungen | Hypotension, palpitations, postural hypotension, syncope, peripheral edema, weight gain, dyspnea, nasal congestion/rhinitis, impotence. |
|---|
| Expositionspfade | Oral. Essentially completely absorbed in man (90% bioavailability). |
|---|
| Toxizitätsübersicht | Terazosin selectively and competitively inhibits vascular postsynaptic alpha(1)-adrenergic receptors, resulting in peripheral vasodilation and a reduction of vascular resistance and blood pressure. Unlike the nonselective alph-adrenergic blockers phenoxybenzamine and phentolamine, terazosin does not block presynaptic alpha(2)-receptors and, hence, does not cause reflex activation of norepinephrine release to produce reflex tachycardia. |
|---|
| Signs and Symptoms | Asthenia, postural hypotension, dizziness, somnolence, nasal congestion/rhinitis. |
|---|
| Carcinogen Classification | No indication of carcinogenicity to humans (not listed by IARC). |
|---|
| Drug Induced Liver Injury | Drug Induced Liver Injury Rank (DILIrank 2.0)Terazosin hydrochloridevNo-DILI-concernNo matchDOI:10.1016/j.drudis.2016.02.015 |
|---|
| Toxicity Data | LD50: 259.3mg/kg (parental-intravenous, Mouse) (A308) |
|---|
